Ron, thanks again.  I rarely miss a day reading this board.  Let's take a likely scenario, we "win" the Markman, but Pubpat initiated re-exam is still pending for 18-24months.

This has three effects IMO......

1.  That it will slow the licensing rate

2.  It may lower the licensing dollars per deal

3.  It may make the deals favor a royalty over a one time payment as the royalty stream would end if the patent is invalidated......whereas a one-time upfront payment I assume is ours to keep no matter the reexam outcome.

I think these effects combine to keep a bit lower mkt cap on the stock.  Even if we settle after Markman or win the trial in November, this cloud will continue to hang and temper the exhuberance that would otherwise create unabated SP rise.

all of course..........IMO

biomedman